Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C37H67NO13.CHNS |
Molecular Weight | 793.017 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 18 / 18 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
SC#N.[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]2[C@H](C)[C@@H](O[C@]3([H])O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]2C
InChI
InChIKey=WVRRTEYLDPNZHR-YZPBMOCRSA-N
InChI=1S/C37H67NO13.CHNS/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26;2-1-3/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3;3H/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-;/m1./s1
DescriptionSources: http://www.przychodnia.pl/el/leki.php3?lek=628http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/061621s039lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050207s071lbl.pdfCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68015643
Sources: http://www.przychodnia.pl/el/leki.php3?lek=628http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/061621s039lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050207s071lbl.pdf
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68015643
Erythromycin ethylsuccinate (E.E.S.®, ERY-PED®) is an ester of erythromycin base and succinic acid. It is suitable for oral administration. Erythromycin is a macrolide antibiotic, produced by Saccharopolyspora erythraea (formerly Streptomyces erythraeus). It acts primarily as a bacteriostatic agent. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erythromycin does not affect nucleic acid synthesis.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15808097http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050207s071lbl.pdf
Curator's Comment: Information about erythromycin ethylsuccinate is unavailable.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2363135 |
14.0 nM [Kd] | ||
Target ID: CHEMBL2363135 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7023159 |
|||
Target ID: CHEMBL2363135 |
14.0 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Erythromycin Approved UseErythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection. Launch Date1972 |
|||
Curative | Erythromycin Approved UseErythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection. Launch Date1972 |
|||
Curative | Erythromycin Approved UseErythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection. Launch Date1972 |
|||
Curative | Erythromycin Approved UseErythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection. Launch Date1972 |
|||
Curative | Erythromycin Approved UseErythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection. Launch Date1972 |
|||
Curative | Davercin Approved UseFor the topical treatment of acne vulgaris |
|||
Curative | Davercin Approved UseFor the topical treatment of pneumonia |
|||
Curative | Davercin Approved UseIndicated for the treatment of bacterial endocarditis |
|||
Curative | Davercin Approved UseUnknown |
|||
Curative | E.E.S. Approved UseE.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below:
Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved).
Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes.
Listeriosis caused by Listeria monocytogenes.
Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals.
Respiratory tract infections due to Mycoplasma pneumoniae.
Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment).
Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers.
Erythrasma: In the treatment of infections due to Corynebacterium minutissimum.
Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only).
Extraenteric amebiasis requires treatment with other agents.
Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months.
Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy.
Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis.
When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum.
Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Launch Date1965 |
|||
Curative | E.E.S. Approved UseE.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below:
Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved).
Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes.
Listeriosis caused by Listeria monocytogenes.
Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals.
Respiratory tract infections due to Mycoplasma pneumoniae.
Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment).
Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers.
Erythrasma: In the treatment of infections due to Corynebacterium minutissimum.
Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only).
Extraenteric amebiasis requires treatment with other agents.
Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months.
Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy.
Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis.
When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum.
Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Launch Date1965 |
|||
Curative | E.E.S Approved UseE.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below:
Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved).
Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes.
Listeriosis caused by Listeria monocytogenes.
Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals.
Respiratory tract infections due to Mycoplasma pneumoniae.
Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment).
Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers.
Erythrasma: In the treatment of infections due to Corynebacterium minutissimum.
Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only).
Extraenteric amebiasis requires treatment with other agents.
Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months.
Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy.
Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis.
When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum.
Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Launch Date1965 |
|||
Curative | E.E.S. Approved UseE.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below:
Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved).
Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes.
Listeriosis caused by Listeria monocytogenes.
Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals.
Respiratory tract infections due to Mycoplasma pneumoniae.
Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment).
Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers.
Erythrasma: In the treatment of infections due to Corynebacterium minutissimum.
Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only).
Extraenteric amebiasis requires treatment with other agents.
Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months.
Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy.
Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis.
When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum.
Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Launch Date1965 |
|||
Curative | E.E.S. Approved UseE.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below:
Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved).
Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes.
Listeriosis caused by Listeria monocytogenes.
Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals.
Respiratory tract infections due to Mycoplasma pneumoniae.
Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment).
Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers.
Erythrasma: In the treatment of infections due to Corynebacterium minutissimum.
Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only).
Extraenteric amebiasis requires treatment with other agents.
Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months.
Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy.
Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis.
When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum.
Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Launch Date1965 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.18 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6628511/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERYTHROMYCIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2.44 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6628511/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERYTHROMYCIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1.62 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6628511/ |
250 mg 4 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ERYTHROMYCIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1.99 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6628511/ |
250 mg 4 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ERYTHROMYCIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1161.5 ng/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERYTHROMYCIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1386.1 ng/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERYTHROMYCIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6628511/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERYTHROMYCIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
6.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6628511/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERYTHROMYCIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3544.7 ng × h/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERYTHROMYCIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4096.7 ng × h/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERYTHROMYCIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.48 h |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERYTHROMYCIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.31 h |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERYTHROMYCIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
5 g 1 times / day single, oral Studied dose Dose: 5 g, 1 times / day Route: oral Route: single Dose: 5 g, 1 times / day Sources: |
healthy, 12 years n = 1 Health Status: healthy Age Group: 12 years Sex: F Population Size: 1 Sources: |
Other AEs: Pancreatitis... |
5.3 g 1 times / day single, oral Studied dose Dose: 5.3 g, 1 times / day Route: oral Route: single Dose: 5.3 g, 1 times / day Sources: |
healthy, 15 years n = 1 Health Status: healthy Age Group: 15 years Sex: F Population Size: 1 Sources: |
Other AEs: Pancreatitis... |
500 mg 2 times / day multiple, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: |
unhealthy, mean age 30 years n = 35 Health Status: unhealthy Condition: maxillary sinusitis Age Group: mean age 30 years Sex: M+F Population Size: 35 Sources: |
Disc. AE: Vomiting... AEs leading to discontinuation/dose reduction: Vomiting (2.8%) Sources: |
500 mg 3 times / day multiple, oral Recommended Dose: 500 mg, 3 times / day Route: oral Route: multiple Dose: 500 mg, 3 times / day Sources: |
unhealthy, mean age 30 years n = 41 Health Status: unhealthy Condition: maxillary sinusitis Age Group: mean age 30 years Sex: M+F Population Size: 41 Sources: |
Disc. AE: Nausea, Abdominal pain... AEs leading to discontinuation/dose reduction: Nausea (14.6%) Sources: Abdominal pain (4.9%) |
500 mg 2 times / day multiple, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: |
unhealthy, mean age 44 years n = 120 Health Status: unhealthy Condition: streptococcal pharyngitis Age Group: mean age 44 years Sex: M+F Population Size: 120 Sources: |
Disc. AE: Epigastralgia, Nausea... AEs leading to discontinuation/dose reduction: Epigastralgia (grade 2-3, 2.5%) Sources: Nausea (grade 3, 3.3%) Vomiting (grade 2, 0.8%) |
100 mg single, intravenous Dose: 100 mg Route: intravenous Route: single Dose: 100 mg Sources: |
unhealthy n = 9 Health Status: unhealthy Condition: Parkinson's Disease Population Size: 9 Sources: |
Other AEs: Akathisia, Diarrhea... Other AEs: Akathisia (below serious, 1 patient) Sources: Diarrhea (below serious, 1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Pancreatitis | 5 g 1 times / day single, oral Studied dose Dose: 5 g, 1 times / day Route: oral Route: single Dose: 5 g, 1 times / day Sources: |
healthy, 12 years n = 1 Health Status: healthy Age Group: 12 years Sex: F Population Size: 1 Sources: |
|
Pancreatitis | 5.3 g 1 times / day single, oral Studied dose Dose: 5.3 g, 1 times / day Route: oral Route: single Dose: 5.3 g, 1 times / day Sources: |
healthy, 15 years n = 1 Health Status: healthy Age Group: 15 years Sex: F Population Size: 1 Sources: |
|
Vomiting | 2.8% Disc. AE |
500 mg 2 times / day multiple, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: |
unhealthy, mean age 30 years n = 35 Health Status: unhealthy Condition: maxillary sinusitis Age Group: mean age 30 years Sex: M+F Population Size: 35 Sources: |
Nausea | 14.6% Disc. AE |
500 mg 3 times / day multiple, oral Recommended Dose: 500 mg, 3 times / day Route: oral Route: multiple Dose: 500 mg, 3 times / day Sources: |
unhealthy, mean age 30 years n = 41 Health Status: unhealthy Condition: maxillary sinusitis Age Group: mean age 30 years Sex: M+F Population Size: 41 Sources: |
Abdominal pain | 4.9% Disc. AE |
500 mg 3 times / day multiple, oral Recommended Dose: 500 mg, 3 times / day Route: oral Route: multiple Dose: 500 mg, 3 times / day Sources: |
unhealthy, mean age 30 years n = 41 Health Status: unhealthy Condition: maxillary sinusitis Age Group: mean age 30 years Sex: M+F Population Size: 41 Sources: |
Vomiting | grade 2, 0.8% Disc. AE |
500 mg 2 times / day multiple, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: |
unhealthy, mean age 44 years n = 120 Health Status: unhealthy Condition: streptococcal pharyngitis Age Group: mean age 44 years Sex: M+F Population Size: 120 Sources: |
Epigastralgia | grade 2-3, 2.5% Disc. AE |
500 mg 2 times / day multiple, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: |
unhealthy, mean age 44 years n = 120 Health Status: unhealthy Condition: streptococcal pharyngitis Age Group: mean age 44 years Sex: M+F Population Size: 120 Sources: |
Nausea | grade 3, 3.3% Disc. AE |
500 mg 2 times / day multiple, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: |
unhealthy, mean age 44 years n = 120 Health Status: unhealthy Condition: streptococcal pharyngitis Age Group: mean age 44 years Sex: M+F Population Size: 120 Sources: |
Akathisia | below serious, 1 patient | 100 mg single, intravenous Dose: 100 mg Route: intravenous Route: single Dose: 100 mg Sources: |
unhealthy n = 9 Health Status: unhealthy Condition: Parkinson's Disease Population Size: 9 Sources: |
Diarrhea | below serious, 1 patient | 100 mg single, intravenous Dose: 100 mg Route: intravenous Route: single Dose: 100 mg Sources: |
unhealthy n = 9 Health Status: unhealthy Condition: Parkinson's Disease Population Size: 9 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
likely | ||||
moderate [IC50 9.9 uM] | yes (co-administration study) Comment: Erythromycin increased mean Cmax value of simvastatin 3.4 fold and AUC0-24 value 6.2 fold; coadministered erythromycin has been reported to increase AUCs of simvastatin, triazolam, and midazolam 6.2-, 3.6-, and 3.8-fold, respectively; A significant increase in colchicine plasma concentration is anticipated when co-administered with moderate CYP3A4 inhibitors such as erythromycin; Page: 10.0 |
|||
yes [IC50 217 uM] | ||||
yes [IC50 22.7 uM] | ||||
yes [IC50 34 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
yes | likely (co-administration study) Comment: Coadministration of erythromycin and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both the therapeutic and adverse effects of the concomitant drug Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050207s074,050611s036lbl.pdf#page=9 Page: 9.0 |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
A C-13 relaxation study on erythromycin A cyclic 11,12-carbonate. | 1978 May |
|
Comparison of the mechanism of action of cyclic 11,12-erythromycin A carbonate and erythromycin A. | 1980 |
|
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs. | 1992 Sep |
|
Evaluation of pertussis treatment with erythromycin ethylsuccinate and stearate according to age. | 1994 Nov |
|
Receptor for motilin identified in the human gastrointestinal system. | 1999 Jun 25 |
|
Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group. | 2000 Jul |
|
Risk of torsades de pointes from oral erythromycin with concomitant carbimazole (methimazole) administration. | 2001 Oct |
|
Studies on macrolide antibiotics I. Synthesis and antibacterial activity of erythromycin A 9-O-substituted oxime ether derivatives against Mycobacterium avium complex. | 2001 Sep |
|
Chlorometabolite production by the ecologically important white rot fungus Bjerkandera adusta. | 2001 Sep |
|
Stereodivergent approach to beta-hydroxy alpha-amino acids from C(2)-symmetrical alk-2-yne-1,4-diols. | 2002 Dec 12 |
|
Stereoselective binding of 2-(4-biphenylyl)-3-substituted-3-hydroxypropionic acids on an immobilised human serum albumin chiral stationary phase. | 2002 Feb 25 |
|
Dynamics of CD34+ progenitor cells following allogeneic bone marrow transplantation in Ph1+CML--an immunohistochemical study on 113 patients with sequential trephine biopsies. | 2002 Jun |
|
Erythro- and threo-2-hydroxynonyl substituted 2-phenyladenines and 2-phenyl-8-azaadenines: ligands for A1 adenosine receptors and adenosine deaminase. | 2002 Mar |
|
Clinical evaluation of Double Strength Isotrexin versus Benzamycin in the topical treatment of mild to moderate acne vulgaris. | 2002 Sep |
|
[Postoperative ileus: part II (Clinical therapy)]. | 2003 Apr |
|
Guaiacylglycerol-7'-O-methyl 8'-vanillic acid ether and related compounds from Boreava orientalis. | 2003 Jan-Feb |
|
A randomized, double-blind, multicenter, parallel group study to compare relative efficacies of the topical gels 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/erythromycin 4% in the treatment of moderate acne vulgaris of the face. | 2003 Jan-Feb |
|
A novel enzyme, D-3-hydroxyaspartate aldolase from Paracoccus denitrificans IFO 13301: purification, characterization, and gene cloning. | 2003 Jul |
|
Stereoselective biosynthesis of chloroarylpropane diols by the basidiomycete Bjerkandera adusta. | 2003 Jul |
|
A novel three-component reaction catalyzed by dirhodium(II) acetate: decomposition of phenyldiazoacetate with arylamine and imine for highly diastereoselective synthesis of 1,2-diamines. | 2003 Oct 16 |
|
erythro-1-Naphthyl-1-(2-piperidyl)methanol: synthesis, resolution, NMR relative configuration, and VCD absolute configuration. | 2003 Sep 19 |
|
Bitterness evaluation of medicines for pediatric use by a taste sensor. | 2004 Aug |
|
Delayed Gastric Emptying in Functional Dyspepsia. | 2004 Aug |
|
Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. | 2004 Dec |
|
Local mechanisms underlying the regulatory effect of Kropanol on hemopoiesis during paradoxical sleep deprivation. | 2004 Feb |
|
Cytochrome P450/NADPH-dependent formation of trans epoxides from trans-arachidonic acids. | 2004 Feb 23 |
|
Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels. | 2004 Jul |
|
Highly diastereoselective reductive coupling of 2-bromo-2,3,3,3-tetrafluoropropanamide with aldehydes promoted by triphenylphosphine-titanium(IV) isopropoxide. An efficient route to the synthesis of erythro-alpha-fluoro-alpha-(trifluoromethyl)-beta-hydroxy amides. | 2004 Jul 23 |
|
Effect of particle size on mixing degree in dispensation. | 2004 Mar |
|
Effect of mixing method on the mixing degree during the preparation of triturations. | 2004 Mar |
|
Anti-proliferative effects of lichen-derived lipoxygenase inhibitors on twelve human cancer cell lines of different tissue origin in vitro. | 2004 Nov |
|
Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia. | 2005 |
|
In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. | 2005 Apr |
|
Comparison of information on the pharmacokinetic interactions of Ca antagonists in the package inserts from three countries (Japan, USA and UK). | 2005 Aug |
|
On the CH...Cu agostic interaction: chiral copper(II) compounds with ephedrine and pseudoephedrine derivatives. | 2005 Aug 14 |
|
On-line identification of sugarcane (Saccharum officinarum L.) methoxyflavones by liquid chromatography-UV detection using post-column derivatization and liquid chromatography-mass spectrometry. | 2005 Jul 29 |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Desensitization of the human motilin receptor by motilides. | 2005 Jun |
|
[Biological effects of a natural alkyl-diacylglyceride preparation in rats with experimental cardioangiopathy]. | 2005 Mar-Apr |
|
The effect of erythromycin and fluvoxamine on the pharmacokinetics of intravenous lidocaine. | 2005 May |
Patents
Sample Use Guides
Initial dose - 30 mg/kg, then 15 mg/kg every 12 hours.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7023159
At the concentration which stops polylysine synthesis by more than 80% (about 0.5 nM/100 pM of 70S ribosomes), the Erythromycin cyclocarbonate inhibited but slightly binding of phage f2 RNA to ribosomes.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
7704-67-8
Created by
admin on Fri Dec 15 14:59:52 GMT 2023 , Edited by admin on Fri Dec 15 14:59:52 GMT 2023
|
PRIMARY | |||
|
DTXSID50858755
Created by
admin on Fri Dec 15 14:59:52 GMT 2023 , Edited by admin on Fri Dec 15 14:59:52 GMT 2023
|
PRIMARY | |||
|
83938
Created by
admin on Fri Dec 15 14:59:52 GMT 2023 , Edited by admin on Fri Dec 15 14:59:52 GMT 2023
|
PRIMARY | |||
|
DBSALT001625
Created by
admin on Fri Dec 15 14:59:52 GMT 2023 , Edited by admin on Fri Dec 15 14:59:52 GMT 2023
|
PRIMARY | |||
|
300000029159
Created by
admin on Fri Dec 15 14:59:52 GMT 2023 , Edited by admin on Fri Dec 15 14:59:52 GMT 2023
|
PRIMARY | |||
|
231-723-1
Created by
admin on Fri Dec 15 14:59:52 GMT 2023 , Edited by admin on Fri Dec 15 14:59:52 GMT 2023
|
PRIMARY | |||
|
Y7A95YRI88
Created by
admin on Fri Dec 15 14:59:52 GMT 2023 , Edited by admin on Fri Dec 15 14:59:52 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD